Form 4: OBIO CEO's Tax Withholding on RSU Vesting

Orchestra BioMed Holdings CEO David P. Hochman reported a disposition of 3,283 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• David P. Hochman, CEO and Chairperson of Orchestra BioMed Holdings, Inc. (OBIO), reported a transaction on November 13, 2025.
• The transaction involved the disposition of 3,283 shares of Common Stock at a price of $4.18 per share.
• This disposition was solely for the purpose of satisfying tax withholding obligations associated with the vesting of restricted stock units.
• No shares were sold in the open market as a result of this vesting and tax satisfaction.
• Following this transaction, Mr. Hochman directly beneficially owns 607,822 shares and indirectly owns 442,765 shares through the DPH 2008 Trust.

Sentiment

Score: 5

Explanation: The transaction is neutral as it represents a routine tax withholding event for RSU vesting, not an open market sale or purchase by an insider.

Positives

• The transaction was a non-market sale, specifically for tax withholding, indicating no intent to sell shares on the open market by the insider.
• The vesting of restricted stock units implies continued compensation and retention of a key executive.

Negatives

• A reduction in direct beneficial ownership by 3,283 shares, although for tax purposes.

Future Outlook

NA

Industry Context

This is a routine insider transaction related to executive compensation and tax obligations, common across all industries for publicly traded companies with RSU programs. It does not reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine tax-related transaction, not an open market sale indicating a change in insider sentiment.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine tax withholding event for restricted stock unit vesting by a key executive. It does not indicate any change in the company's fundamentals, strategic direction, or the executive's confidence in the company. Therefore, it provides no basis for a change in investment recommendation, and a 'hold' stance is maintained.

Keywords

Orchestra BioMed Holdings, OBIO, David P Hochman, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Beneficial Ownership